# X4 Pharmaceuticals Extends Commercial Runway

> X4 Pharmaceuticals secures $150m debt facility to extend commercial runway for XOLREMDI and mavorixafor.
- Title: X4 Pharmaceuticals Extends Commercial Runway | Shortify
- Summary: X4 Pharmaceuticals secures $150m debt facility to extend commercial runway for XOLREMDI and mavorixafor. X4 Pharmaceuticals secured a $150 million debt…
- Keywords: x4 pharmaceuticals, xfor, xolremdi, mavorixafor, 4ward trial, debt facility, whim syndrome, neutropenia, Pharmaceuticals, Extends, Commercial, Runway
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/x4-pharmaceuticals-xfor-new-debt-facility-extends-the-commercial-runway-test
- Author: Newsdesk
- Published: 2026-10-09T12:14:54+00:00
- Read time: 1 min
- Topics: x4 pharmaceuticals, xfor, xolremdi, mavorixafor, 4ward trial, debt facility, whim syndrome, neutropenia
## X4 Pharmaceuticals secures debt facility
X4 Pharmaceuticals secured a senior debt facility of up to $150 million with K2 HealthVentures on October 8, 2026.
## XOLREMDI approved for WHIM syndrome
XOLREMDI is approved in the U.S. as an oral, once-daily therapy to increase circulating mature neutrophils and lymphocytes in patients 12 years and older with WHIM syndrome.
## 4WARD trial enrollment target
X4 expects to complete enrollment in the global pivotal Phase 3 4WARD trial by year-end 2026 and report topline data in the first half of 2028.
## Q2 2026 financial results
X4 reported a net loss of $16.2 million for the quarter ended June 30, 2026, compared with $25.7 million in the prior-year period.
## Debt facility structure details
The K2 facility provides term loans of up to $150 million with the first tranche of $80 million funded at closing to repay prior obligations.
## Interest terms and conditions
Loans carry cash interest at a variable annual rate equal to the greater of 8.55% or Wall Street Journal prime rate plus 1.55%, with interest-only payments through October 1, 2029.
## Investor watch items
X4’s commercial trajectory, 4WARD timeline, and access to the remaining $70 million under the K2 facility are key investor watch items.
## Key takeaway

X4 Pharmaceuticals secured a $150 million debt facility with K2 HealthVentures to extend its commercial runway while awaiting pivotal 4WARD trial results.